Vgi Partners Asian
- Short interest
- 0.00%
- +0.02 pp 30d
- as of 17 June 2026
- Reported shorts
- 55
- Shares on issue
- 215.534M
Vgi Partners Asian (VFY) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $168.7Kvs $65.1K (FY25)
- Yahoo Finance, as at 14 Oct 2026
- NPAT
- −$16.2Mvs −$32.7M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- EPS (diluted)
- −$0.25T (source: Derived: trailing 12 months at year end)vs −$0.73 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- +159.1%FY
- EPS YoY
- n/aTTM
- Derived: trailing 12 months at year end
Summary of FY26 Appendix 4E and Annual Report, 4 Aug 2026
Vitrafy Life Sciences reported a net loss after tax of $16.17 million for FY2026, a 50.6% improvement from the prior year's $32.71 million loss, while revenue and other income rose 80.0% to $3.66 million. No dividends were paid or declared. The company is in an investment phase, focusing on commercialising its cryopreservation technology, with cash and term deposits of $41.2 million at year-end and plans to scale manufacturing and pursue FDA registration in FY2027.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 14 Oct 2026
- Gross margin
- 100.0%
- Operating margin
- −12,112.5%
- Net margin
- −9,584.2%
- FCF margin
- −9,667.1%
- ROE
- −46.3%
- ROA
- −43.1%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $26.1M
- Net debt / EBITDA
- n/a
- Current ratio
- 23.8×
- Interest cover
- −7,738.3×
- Cash dividends paid / net profit
- n/a
- Market cap
- $229.2M
- P/E
- n/a
- P/B
- 5.6×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $168.7K | $65.1K | $37.0K | $32.0K |
| Gross profit | $168.7K | $65.1K | $37.0K | $32.0K |
| Operating income | −$20.4M | −$16.6M | −$10.7M | −$9.2M |
| EBITDA | −$16.0M | −$26.1M | $7.0K | −$2.8M |
| EBIT | −$16.2M | −$26.2M | $7.0K | −$2.8M |
| Interest expense | $2.6K | $6.5M | $10.4M | $5.0M |
| Pretax income | −$16.2M | −$32.7M | −$10.4M | −$7.8M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$16.2M | −$32.7M | −$10.4M | −$7.8M |
| Net interest income | $776.0K | −$5.7M | −$10.4M | −$5.0M |
| EPS basic | −$0.25T (source: Derived: trailing 12 months at year end) | −$0.73 | −$0.16 | −$0.12 |
| EPS diluted | −$0.25T (source: Derived: trailing 12 months at year end) | −$0.73 | −$0.16 | −$0.12 |
| Shares | 75.4M | 63.8M | 63.8M | 63.8M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4D & 1H26 Financial ReportHalf Year Results13 Feb 2026via asx_announcements
- Appendix 4E and FY25 Annual Report 6cps Final DividendAnnual Results18 Aug 2025via asx_announcements
- Appendix 4D and 1H25 Financial ReportHalf Year Results13 Feb 2025via asx_announcements
- Appendix 4E and FY24 Annual Report, 5cps Final DividendAnnual Results21 Aug 2024via asx_announcements
- Appendix 4D and 1H24 Half Year Report, 5cps Interim DividendHalf Year Results8 Feb 2024via asx_announcements
- 2023 Annual General Meeting - Chairman's AddressAgm Address30 Nov 2023via asx_announcements
- 2023 Annual General Meeting ResultsAgm Address30 Nov 2023via asx_announcements
- Notice of 2023 Annual General MeetingAgm Address30 Oct 2023via asx_announcements
- Annual General Meeting and Director NominationAgm Address20 Sep 2023via asx_announcements
- Appendix 4E and FY23 Annual Report, 5cps Final DividendAnnual Results17 Aug 2023via asx_announcements
Showing 10 of 36 reports